Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development

References

1. 1.↵
   2. Starnes CO.

   Coley’s toxins in perspective. Nature. 1992; 357: 11–2.

   OpenUrlCrossRefPubMedWeb of Science
2. 2.↵
   2. Morales A,
   3. Eidinger D,
   4. Bruce AW.

   Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976; 116: 180–3.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Steinman RM,
   3. Cohn ZA.

   Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973; 137: 1142–62.

   OpenUrlAbstract
4. 4.↵
   2. Van der Bruggen P,
   3. Traversari C,
   4. Chomez P,
   5. Lurquin C,
   6. De Plaen E,
   7. Van den Eynde B, et al.

   A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991; 254: 1643–7.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Faries MB,
   3. Hsueh EC,
   4. Ye X,
   5. Hoban M,
   6. Morton DL.

   Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009; 15: 7029–35.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   2. Kantoff PW,
   3. Higano CS,
   4. Shore ND,
   5. Berger ER,
   6. Small EJ,
   7. Penson DF, et al.

   Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411–22.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   2. Kulkarni P,
   3. Shiraishi T,
   4. Rajagopalan K,
   5. Kim R,
   6. Mooney SM,
   7. Getzenberg RH.

   Cancer/testis antigens and urological malignancies. Nat Rev Urol. 2012; 9: 386–96.

   OpenUrlPubMed
8. 8.
   2. Delamarre L,
   3. Mellman I,
   4. Yadav M.

   Cancer immunotherapy. Neo approaches to cancer vaccines. Science. 2015; 348: 760–1.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   2. Tanyi JL,
   3. Bobisse S,
   4. Ophir E,
   5. Tuyaerts S,
   6. Roberti A,
   7. Genolet R, et al.

   Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. Sci Transl Med. 2018; 10: eaao5931.
10. 10.↵
    2. Walter S,
    3. Weinschenk T,
    4. Stenzl A,
    5. Zdrojowy R,
    6. Pluzanska A,
    7. Szczylik C, et al.

    Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18: 1254–61.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Noguchi M,
    3. Arai G,
    4. Matsumoto K,
    5. Naito S,
    6. Moriya F,
    7. Suekane S, et al.

    Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol Immunother. 2015; 64: 493–505.

    OpenUrl
12. 12.↵
    2. Carreno BM,
    3. Magrini V,
    4. Becker-Hapak M,
    5. Kaabinejadian S,
    6. Hundal J,
    7. Petti AA, et al.

    Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science. 2015; 348: 803–8.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    2. Sahin U,
    3. Derhovanessian E,
    4. Miller M,
    5. Kloke BP,
    6. Simon P,
    7. Löwer M, et al.

    Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2017; 547: 222–6.

    OpenUrlCrossRefPubMed
14. 14.↵
    2. Ott PA,
    3. Hu Z,
    4. Keskin DB,
    5. Shukla SA,
    6. Sun J,
    7. Bozym DJ, et al.

    An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017; 547: 217–21.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Keskin DB,
    3. Anandappa AJ,
    4. Sun J,
    5. Tirosh I,
    6. Mathewson ND,
    7. Li S, et al.

    Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019; 565: 234–9.

    OpenUrlPubMed
16. 16.↵
    2. Hollingsworth RE,
    3. Jansen K.

    Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 2019; 4: 7.

    OpenUrl
17. 17.↵
    2. Martin JD,
    3. Cabral H,
    4. Stylianopoulos T,
    5. Jain RK.

    Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020; 17: 251–66.

    OpenUrl
18. 18.↵
    2. Waldman AD,
    3. Fritz JM,
    4. Lenardo MJ.

    A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020; 20: 651–68.

    OpenUrlPubMed
19. 19.↵
    2. Phuengkham H,
    3. Song C,
    4. Lim YT.

    A designer scaffold with immune nanoconverters for reverting immunosuppression and enhancing immune checkpoint blockade therapy. Adv Mater. 2019; 31: e1903242.
20. 20.↵
    2. Alexandrov LB,
    3. Nik-Zainal S,
    4. Wedge DC,
    5. Aparicio SA,
    6. Behjati S,
    7. Biankin AV, et al.

    Signatures of mutational processes in human cancer. Nature. 2013; 500: 415–21.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    2. Laumont CM,
    3. Vincent K,
    4. Hesnard L,
    5. Audemard É,
    6. Bonneil É,
    7. Laverdure JP, et al.

    Noncoding regions are the main source of targetable tumor-specific antigens. Sci Transl Med. 2018; 10: eaau5516.
22. 22.↵
    2. Smart AC,
    3. Margolis CA,
    4. Pimentel H,
    5. He MX,
    6. Miao D,
    7. Adeegbe D, et al.

    Intron retention is a source of neoepitopes in cancer. Nat Biotechnol. 2018; 36: 1056–8.

    OpenUrl
23. 23.↵
    2. Yamamoto TN,
    3. Kishton RJ,
    4. Restifo NP.

    Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat Med. 2019; 25: 1488–99.

    OpenUrlCrossRefPubMed
24. 24.↵
    2. Harari A,
    3. Graciotti M,
    4. Bassani-Sternberg M,
    5. Kandalaft LE.

    Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020; 19: 635–52.

    OpenUrl
25. 25.↵
    2. Richters MM,
    3. Xia H,
    4. Campbell KM,
    5. Gillanders WE,
    6. Griffith OL,
    7. Griffith M.

    Best practices for bioinformatic characterization of neoantigens for clinical utility. Genome Med. 2019; 11: 56.

    OpenUrlCrossRef
26. 26.↵
    2. Yewdell JW,
    3. Dersh D,
    4. Fåhraeus R.

    Peptide channeling: the key to MHC class I immunosurveillance? Trends Cell Biol. 2019; 29: 929–39.

    OpenUrl
27. 27.↵
    2. Desrichard A,
    3. Snyder A,
    4. Chan TA.

    Cancer neoantigens and applications for immunotherapy. Clin Cancer Res. 2016; 22: 807–12.

    OpenUrlAbstract/FREE Full Text
28. 28.↵
    2. Aikins ME,
    3. Xu C,
    4. Moon JJ.

    Engineered nanoparticles for cancer vaccination and immunotherapy. Acc Chem Res. 2020; 53: 2094–105.

    OpenUrl
29. 29.↵
    2. Li WH,
    3. Li YM.

    Chemical strategies to boost cancer caccines. Chem Rev. 2020; 120: 11420–78.

    OpenUrl
30. 30.↵
    2. Roy S,
    3. Sethi TK,
    4. Taylor D,
    5. Kim YJ,
    6. Johnson DB.

    Breakthrough concepts in immune-oncology: cancer vaccines at the bedside. J Leukoc Biol. 2020; 108: 1455–89.

    OpenUrl
31. 31.↵
    2. Smith CC,
    3. Selitsky SR,
    4. Chai S,
    5. Armistead PM,
    6. Vincent BG,
    7. Serody JS.

    Alternative tumour-specific antigens. Nat Rev Cancer. 2019; 19: 465–78.

    OpenUrlCrossRefPubMed
32. 32.↵
    2. Servin-Blanco R,
    3. Zamora-Alvarado R,
    4. Gevorkian G,
    5. Manoutcharian K.

    Antigenic variability: obstacles on the road to vaccines against traditionally difficult targets. Hum Vaccin Immunother. 2016; 12: 2640–8.

    OpenUrlCrossRef
33. 33.↵
    2. Hu Z,
    3. Ott PA,
    4. Wu CJ.

    Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2018; 18: 168–82.

    OpenUrlCrossRefPubMed
34. 34.↵
    2. Melero I,
    3. Gaudernack G,
    4. Gerritsen W,
    5. Huber C,
    6. Parmiani G,
    7. Scholl S, et al.

    Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol. 2014; 11: 509–24.

    OpenUrlCrossRefPubMed
35. 35.↵
    2. Gross DA,
    3. Graff-Dubois S,
    4. Opolon P,
    5. Cornet S,
    6. Alves P,
    7. Bennaceur-Griscelli A, et al.

    High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. J Clin Invest. 2004; 113: 425–33.

    OpenUrlCrossRefPubMed
36. 36.↵
    2. Kalaora S,
    3. Wolf Y,
    4. Feferman T,
    5. Barnea E,
    6. Greenstein E,
    7. Reshef D, et al.

    Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 2018; 8: 1366–75.

    OpenUrlAbstract/FREE Full Text
37. 37.↵
    2. Bassani-Sternberg M,
    3. Pletscher-Frankild S,
    4. Jensen LJ,
    5. Mann M.

    Mass spectrometry of human leukocyte antigen class I peptidomes reveals strong effects of protein abundance and turnover on antigen presentation. Mol Cell Proteomics. 2015; 14: 658–73.

    OpenUrlAbstract/FREE Full Text
38. 38.↵
    2. Yadav M,
    3. Jhunjhunwala S,
    4. Phung QT,
    5. Lupardus P,
    6. Tanguay J,
    7. Bumbaca S, et al.

    Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature. 2014; 515: 572–6.

    OpenUrlCrossRefPubMedWeb of Science
39. 39.↵
    2. Haen SP,
    3. Löffler MW,
    4. Rammensee HG,
    5. Brossart P.

    Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat Rev Clin Oncol. 2020; 17: 595–610.

    OpenUrl
40. 40.↵
    2. Adhikari AN,
    3. Gallagher RC,
    4. Wang Y,
    5. Currier RJ,
    6. Amatuni G,
    7. Bassaganyas L, et al.

    The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat Med. 2020; 26: 1392–7.

    OpenUrl
41. 41.↵
    2. Bibli SI,
    3. Hu J,
    4. Looso M,
    5. Weigert A,
    6. Ratiu C,
    7. Wittig J, et al.

    Mapping the endothelial cell S-sulfhydrome highlights the crucial role of integrin sulfhydration in vascular function. Circulation. 2021; 143: 935–48.

    OpenUrl
42. 42.↵
    2. Liu Z,
    3. Li JP,
    4. Chen M,
    5. Wu M,
    6. Shi Y,
    7. Li W, et al.

    Detecting tumor antigen-specific T cells via interaction-dependent fucosyl-biotinylation. Cell. 2020; 183: 1117–33 e19.

    OpenUrl
43. 43.↵
    2. Kishton RJ,
    3. Lynn RC,
    4. Restifo NP.

    Strength in numbers: identifying neoantigen targets for cancer immunotherapy. Cell. 2020; 183: 591–3.

    OpenUrl
44. 44.↵
    2. Trinh A,
    3. Polyak K.

    Tumor neoantigens: when too much of a good thing is bad. Cancer Cell. 2019; 36: 466–7.

    OpenUrl
45. 45.↵
    2. Hilf N,
    3. Kuttruff-Coqui S,
    4. Frenzel K,
    5. Bukur V,
    6. Stevanović S,
    7. Gouttefangeas C, et al.

    Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 2019; 565: 240–5.

    OpenUrlCrossRefPubMed
46. 46.↵
    2. Tran E,
    3. Turcotte S,
    4. Gros A,
    5. Robbins PF,
    6. Lu YC,
    7. Dudley ME, et al.

    Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344: 641–5.

    OpenUrlAbstract/FREE Full Text
47. 47.↵
    2. Wells DK,
    3. van Buuren MM,
    4. Dang KK,
    5. Hubbard-Lucey VM,
    6. Sheehan KCF,
    7. Campbell KM, et al.

    Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction. Cell. 2020; 183: 818–34 e13.

    OpenUrl
48. 48.↵
    2. Roudko V,
    3. Bozkus CC,
    4. Orfanelli T,
    5. McClain CB,
    6. Carr C,
    7. O’Donnell T, et al.

    Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors. Cell. 2020; 183: 1634–49 e17.

    OpenUrlPubMed
49. 49.↵
    2. Pettitt SJ,
    3. Frankum JR,
    4. Punta M,
    5. Lise S,
    6. Alexander J,
    7. Chen Y, et al.

    Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov. 2020; 10: 1475–88.

    OpenUrlAbstract/FREE Full Text
50. 50.↵
    2. Van den Eynden J,
    3. Jimenez-Sanchez A,
    4. Miller ML,
    5. Larsson E.

    Lack of detectable neoantigen depletion signals in the untreated cancer genome. Nat Genet. 2019; 51: 1741–8.

    OpenUrl
51. 51.↵
    2. Bassani-Sternberg M,
    3. Braunlein E,
    4. Klar R,
    5. Engleitner T,
    6. Sinitcyn P,
    7. Audehm S, et al.

    Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun. 2016; 7: 13404.
52. 52.↵
    2. Bonsack M,
    3. Hoppe S,
    4. Winter J,
    5. Tichy D,
    6. Zeller C,
    7. Kupper MD, et al.

    Performance evaluation of MHC class-I binding prediction tools based on an experimentally validated MHC-peptide binding data set. Cancer Immunol Res. 2019; 7: 719–36.

    OpenUrlAbstract/FREE Full Text
53. 53.↵
    2. Hundal J,
    3. Kiwala S,
    4. McMichael J,
    5. Miller CA,
    6. Xia H,
    7. Wollam AT, et al.

    pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol Res. 2020; 8: 409–20.

    OpenUrlAbstract/FREE Full Text
54. 54.↵
    2. Reynisson B,
    3. Alvarez B,
    4. Paul S,
    5. Peters B,
    6. Nielsen M.

    NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 2020; 48: W449–54.

    OpenUrlPubMed
55. 55.↵
    2. Chen B,
    3. Khodadoust MS,
    4. Olsson N,
    5. Wagar LE,
    6. Fast E,
    7. Liu CL, et al.

    Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 2019; 37: 1332–43.

    OpenUrlPubMed
56. 56.↵
    2. Nielsen M,
    3. Lundegaard C,
    4. Blicher T,
    5. Lamberth K,
    6. Harndahl M,
    7. Justesen S, et al.

    NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One. 2007; 2: e796.
57. 57.↵
    2. Shemesh CS,
    3. Hsu JC,
    4. Hosseini I,
    5. Shen BQ,
    6. Rotte A,
    7. Twomey P, et al.

    Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021; 29: 555–70.

    OpenUrl
58. 58.↵
    2. Axelrod ML,
    3. Cook RS,
    4. Johnson DB,
    5. Balko JM.

    Biological consequences of MHC-II expression by tumor cells in cancer. Clin Cancer Res. 2019; 25: 2392–402.

    OpenUrlAbstract/FREE Full Text
59. 59.
    2. Alspach E,
    3. Lussier D,
    4. Miceli A,
    5. Kizhvatov I,
    6. DuPage M,
    7. Luoma A, et al.

    MHC-II neoantigens shape tumour immunity and response to immunotherapy. Nature. 2019; 574: 696–701.

    OpenUrlCrossRefPubMed
60. 60.↵
    2. Marty Pyke R,
    3. Thompson WK,
    4. Salem RM,
    5. Font-Burgada J,
    6. Zanetti M,
    7. Carter H.

    Evolutionary pressure against MHC class II binding cancer mutations. Cell. 2018; 175: 1991.

    OpenUrl
61. 61.↵
    2. Anandappa AJ,
    3. Wu CJ,
    4. Ott PA.

    Directing traffic: how to effectively drive T cells into tumors. Cancer Discov. 2020; 10: 185–97.

    OpenUrlAbstract/FREE Full Text
62. 62.↵
    2. Wang H,
    3. Sobral MC,
    4. Zhang DKY,
    5. Cartwright AN,
    6. Li AW,
    7. Dellacherie MO, et al.

    Metabolic labeling and targeted modulation of dendritic cells. Nat Mater. 2020; 19: 1244–52.

    OpenUrl
63. 63.↵
    2. Liu S,
    3. Jiang Q,
    4. Zhao X,
    5. Zhao R,
    6. Wang Y,
    7. Wang Y, et al.

    A DNA nanodevice-based vaccine for cancer immunotherapy. Nat Mater. 2020; 20: 421–30.

    OpenUrl
64. 64.↵
    2. Bourquin J,
    3. Milosevic A,
    4. Hauser D,
    5. Lehner R,
    6. Blank F,
    7. Petri-Fink A, et al.

    Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials. Adv Mater. 2018; 30: e1704307.
65. 65.↵
    2. Rietwyk S,
    3. Peer D.

    Next-generation lipids in RNA interference therapeutics. ACS Nano. 2017; 11: 7572–86.

    OpenUrl
66. 66.↵
    2. Rideau E,
    3. Dimova R,
    4. Schwille P,
    5. Wurm FR,
    6. Landfester K.

    Liposomes and polymersomes: a comparative review towards cell mimicking. Chem Soc Rev. 2018; 47: 8572–610.

    OpenUrlCrossRef
67. 67.↵
    2. Allison AC,
    3. Gregoriadis G.

    Liposomes as immunological adjuvants. Nature. 1974; 252: 252–2.

    OpenUrlPubMed
68. 68.↵
    2. Wicki A,
    3. Witzigmann D,
    4. Balasubramanian V,
    5. Huwyler J.

    Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release. 2015; 200: 138–57.

    OpenUrlCrossRefPubMedWeb of Science
69. 69.↵
    2. Butts C,
    3. Murray N,
    4. Maksymiuk A,
    5. Goss G,
    6. Marshall E,
    7. Soulieres D, et al.

    Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6674–81.

    OpenUrlAbstract/FREE Full Text
70. 70.↵
    2. Shahum E,
    3. Therien HM.

    Immunopotentiation of the humoral response by liposomes: encapsulation versus covalent linkage. Immunology. 1988; 65: 315–7.

    OpenUrlPubMed
71. 71.↵
    2. Noble GT,
    3. Stefanick JF,
    4. Ashley JD,
    5. Kiziltepe T,
    6. Bilgicer B.

    Ligand-targeted liposome design: challenges and fundamental considerations. Trends Biotechnol. 2014; 32: 32–45.

    OpenUrlCrossRefPubMedWeb of Science
72. 72.↵
    2. Jayaraman M,
    3. Ansell SM,
    4. Mui BL,
    5. Tam YK,
    6. Chen J,
    7. Du X, et al.

    Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo. Angew Chem Int Ed Engl. 2012; 51: 8529–33.

    OpenUrlCrossRefPubMedWeb of Science
73. 73.↵
    2. Cullis PR,
    3. Hope MJ.

    Lipid nanoparticle systems for enabling gene therapies. Mol Ther. 2017; 25: 1467–75.

    OpenUrl
74. 74.↵
    2. Newcomb CJ,
    3. Sur S,
    4. Ortony JH,
    5. Lee OS,
    6. Matson JB,
    7. Boekhoven J, et al.

    Cell death versus cell survival instructed by supramolecular cohesion of nanostructures. Nat Commun. 2014; 5: 3321.

    OpenUrl
75. 75.↵
    2. Zhu D,
    3. Hu C,
    4. Fan F,
    5. Qin Y,
    6. Huang C,
    7. Zhang Z, et al.

    Co-delivery of antigen and dual agonists by programmed mannose-targeted cationic lipid-hybrid polymersomes for enhanced vaccination. Biomaterials. 2019; 206: 25–40.

    OpenUrl
76. 76.↵
    2. Marty R,
    3. N’Soukpoe-Kossi CN,
    4. Charbonneau D,
    5. Weinert CM,
    6. Kreplak L,
    7. Tajmir-Riahi HA.

    Structural analysis of DNA complexation with cationic lipids. Nucleic Acids Res. 2009; 37: 849–57.

    OpenUrlCrossRefPubMedWeb of Science
77. 77.↵
    2. Courant T,
    3. Bayon E,
    4. Reynaud-Dougier HL,
    5. Villiers C,
    6. Menneteau M,
    7. Marche PN, et al.

    Tailoring nanostructured lipid carriers for the delivery of protein antigens: Physicochemical properties versus immunogenicity studies. Biomaterials. 2017; 136: 29–42.

    OpenUrl
78. 78.↵
    2. Sekiya T,
    3. Yamagishi J,
    4. Gray JHV,
    5. Whitney PG,
    6. Martinelli A,
    7. Zeng W, et al.

    PEGylation of a TLR2-agonist-based vaccine delivery system improves antigen trafficking and the magnitude of ensuing antibody and CD8(+) T cell responses. Biomaterials. 2017; 137: 61–72.

    OpenUrlCrossRef
79. 79.↵
    2. Warriner HE,
    3. Idziak SH,
    4. Slack NL,
    5. Davidson P,
    6. Safinya CR.

    Lamellar biogels: fluid-membrane-based hydrogels containing polymer lipids. Science. 1996; 271: 969–73.

    OpenUrlAbstract/FREE Full Text
80. 80.↵
    2. Uchida T,
    3. Taneichi M.

    Clinical application of surface-linked liposomal antigens. Mini Rev Med Chem. 2008; 8: 184–92.

    OpenUrlPubMed
81. 81.↵
    2. Chen D,
    3. Love KT,
    4. Chen Y,
    5. Eltoukhy AA,
    6. Kastrup C,
    7. Sahay G, et al.

    Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation. J Am Chem Soc. 2012; 134: 6948–51.

    OpenUrlCrossRefPubMedWeb of Science
82. 82.
    2. Stroock AD,
    3. Dertinger SK,
    4. Ajdari A,
    5. Mezic I,
    6. Stone HA,
    7. Whitesides GM.

    Chaotic mixer for microchannels. Science. 2002; 295: 647–51.

    OpenUrlAbstract/FREE Full Text
83. 83.↵
    2. Grimaldi N,
    3. Andrade F,
    4. Segovia N,
    5. Ferrer-Tasies L,
    6. Sala S,
    7. Veciana J, et al.

    Lipid-based nanovesicles for nanomedicine. Chem Soc Rev. 2016; 45: 6520–45.

    OpenUrlCrossRef
84. 84.↵
    2. Love KT,
    3. Mahon KP,
    4. Levins CG,
    5. Whitehead KA,
    6. Querbes W,
    7. Dorkin JR, et al.

    Lipid-like materials for low-dose, in vivo gene silencing. Proc Natl Acad Sci U S A. 2010; 107: 1864–9.

    OpenUrlAbstract/FREE Full Text
85. 85.↵
    2. Kim Y,
    3. Kang S,
    4. Shin H,
    5. Kim T,
    6. Yu B,
    7. Kim J, et al.

    Sequential and timely combination of a cancer nanovaccine with immune checkpoint blockade effectively inhibits tumor growth and relapse. Angew Chem Int Ed Engl. 2020; 59: 14628–38.

    OpenUrl
86. 86.↵
    2. Fan Y,
    3. Stronsky SM,
    4. Xu Y,
    5. Steffens JT,
    6. van Tongeren SA,
    7. Erwin A, et al.

    Multilamellar vaccine particle elicits potent immune activation with protein antigens and protects mice against Ebola virus infection. ACS Nano. 2019; 13: 11087–96.

    OpenUrl
87. 87.↵
    2. Yu X,
    3. Dai Y,
    4. Zhao Y,
    5. Qi S,
    6. Liu L,
    7. Lu L, et al.

    Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response. Nat Commun. 2020; 11: 1110.

    OpenUrl
88. 88.↵
    2. Kranz LM,
    3. Diken M,
    4. Haas H,
    5. Kreiter S,
    6. Loquai C,
    7. Reuter KC, et al.

    Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature. 2016; 534: 396–401.

    OpenUrlCrossRefPubMed
89. 89.↵
    2. Miao L,
    3. Li L,
    4. Huang Y,
    5. Delcassian D,
    6. Chahal J,
    7. Han J, et al.

    Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat Biotechnol. 2019; 37: 1174–85.

    OpenUrl
90. 90.↵
    2. Sayour EJ,
    3. Grippin A,
    4. De Leon G,
    5. Stover B,
    6. Rahman M,
    7. Karachi A, et al.

    Personalized tumor RNA loaded lipid-nanoparticles prime the systemic and intratumoral milieu for response to cancer immunotherapy. Nano Lett. 2018; 18: 6195–206.

    OpenUrl
91. 91.↵
    2. Pardi N,
    3. Hogan MJ,
    4. Naradikian MS,
    5. Parkhouse K,
    6. Cain DW,
    7. Jones L, et al.

    Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J Exp Med. 2018; 215: 1571–88.

    OpenUrlAbstract/FREE Full Text
92. 92.↵
    2. Coolen AL,
    3. Lacroix C,
    4. Mercier-Gouy P,
    5. Delaune E,
    6. Monge C,
    7. Exposito JY, et al.

    Poly(lactic acid) nanoparticles and cell-penetrating peptide potentiate mRNA-based vaccine expression in dendritic cells triggering their activation. Biomaterials. 2019; 195: 23–37.

    OpenUrlCrossRef
93. 93.↵
    2. Li Y,
    3. Su Z,
    4. Zhao W,
    5. Zhang X,
    6. Momin N,
    7. Zhang C, et al.

    Multifunctional oncolytic nanoparticles deliver self-replicating IL-12 RNA to eliminate established tumors and prime systemic immunity. Nature Cancer. 2020; 1: 882–93.

    OpenUrl
94. 94.↵
    2. Walsh EE,
    3. Frenck RW Jr..,
    4. Falsey AR,
    5. Kitchin N,
    6. Absalon J,
    7. Gurtman A, et al.

    Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020; 383: 2439–50.

    OpenUrlCrossRefPubMed
95. 95.↵
    2. Sahin U,
    3. Karikó K,
    4. Türeci Ö.

    mRNA-based therapeutics – developing a new class of drugs. Nat Rev Drug Discov. 2014; 13: 759–80.

    OpenUrlCrossRefPubMed
96. 96.↵
    2. Pardi N,
    3. Hogan MJ,
    4. Porter FW,
    5. Weissman D.

    mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov. 2018; 17: 261–79.

    OpenUrlCrossRefPubMed
97. 97.↵
    2. Bookstaver ML,
    3. Tsai SJ,
    4. Bromberg JS,
    5. Jewell CM.

    Improving vaccine and immunotherapy design using biomaterials. Trends Immunol. 2018; 39: 135–50.

    OpenUrlCrossRef
98. 98.↵
    2. Salazar LG,
    3. Lu H,
    4. Reichow JL,
    5. Childs JS,
    6. Coveler AL,
    7. Higgins DM, et al.

    Topical imiquimod plus nab-paclitaxel for breast cancer cutaneous metastases: a phase 2 clinical trial. JAMA Oncol. 2017; 3: 969–73.

    OpenUrl
99. 99.↵
    2. Garrido-Laguna I,
    3. Hidalgo M.

    Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015; 12: 319–34.

    OpenUrlCrossRefPubMed
100. 100.↵
     2. Mohan K,
     3. Ganesan AR,
     4. Muralisankar T,
     5. Jayakumar R,
     6. Sathishkumar P,
     7. Uthayakumar V, et al.

     Recent insights into the extraction, characterization, and bioactivities of chitin and chitosan from insects. Trends Food Sci Technol. 2020; 105: 17–42.

     OpenUrl
101. 101.↵
     2. Qin L,
     3. Cao J,
     4. Shao K,
     5. Tong F,
     6. Yang Z,
     7. Lei T, et al.

     A tumor-to-lymph procedure navigated versatile gel system for combinatorial therapy against tumor recurrence and metastasis. Sci Adv. 2020; 6: eabb3116.
102. 102.↵
     2. Ryu JH,
     3. Yoon HY,
     4. Sun IC,
     5. Kwon IC,
     6. Kim K.

     Tumor-targeting glycol chitosan nanoparticles for cancer heterogeneity. Adv Mater. 2020; 32: e2002197.
103. 103.↵
     2. Xu J,
     3. Xu B,
     4. Tao J,
     5. Yang Y,
     6. Hu Y,
     7. Huang Y.

     Microneedle-assisted, DC-targeted codelivery of pTRP-2 and adjuvant of paclitaxel for transcutaneous immunotherapy. Small. 2017; 13: 1700666.
104. 104.↵
     2. Saini P,
     3. Arora M,
     4. Kumar M.

     Poly(lactic acid) blends in biomedical applications. Adv Drug Deliv Rev. 2016; 107: 47–59.

     OpenUrl
105. 105.
     2. Lu L,
     3. Yaszemski MJ,
     4. Mikos AG.

     Retinal pigment epithelium engineering using synthetic biodegradable polymers. Biomaterials. 2001; 22: 3345–55.

     OpenUrlCrossRefPubMedWeb of Science
106. 106.↵
     2. Saito N,
     3. Murakami N,
     4. Takahashi J,
     5. Horiuchi H,
     6. Ota H,
     7. Kato H, et al.

     Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv Drug Deliv Rev. 2005; 57: 1037–48.

     OpenUrlCrossRefPubMed
107. 107.
     2. Duncan R,
     3. Vicent MJ.

     Polymer therapeutics-prospects for 21st century: the end of the beginning. Adv Drug Deliv Rev. 2013; 65: 60–70.

     OpenUrlCrossRefPubMed
108. 108.↵
     2. Xie X,
     3. Hu Y,
     4. Ye T,
     5. Chen Y,
     6. Zhou L,
     7. Li F, et al.

     Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen. Nat Biomed Eng. 2020.
109. 109.↵
     2. Panyam J,
     3. Labhasetwar V.

     Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003; 55: 329–47.

     OpenUrlCrossRefPubMedWeb of Science
110. 110.↵
     2. Roy S,
     3. Zhu D,
     4. Parak WJ,
     5. Feliu N.

     Lysosomal proton buffering of poly(ethylenimine) measured in situ by fluorescent pH-sensor microcapsules. ACS Nano. 2020; 14: 8012–23.

     OpenUrl
111. 111.↵
     2. Wei X,
     3. Shao B,
     4. He Z,
     5. Ye T,
     6. Luo M,
     7. Sang Y, et al.

     Cationic nanocarriers induce cell necrosis through impairment of Na(+)/K(+)-ATPase and cause subsequent inflammatory response. Cell Res. 2015; 25: 237–53.

     OpenUrlCrossRefPubMed
112. 112.↵
     2. Gong N,
     3. Zhang Y,
     4. Teng X,
     5. Wang Y,
     6. Huo S,
     7. Qing G, et al.

     Proton-driven transformable nanovaccine for cancer immunotherapy. Nat Nanotechnol. 2020; 15: 1053–64.

     OpenUrl
113. 113.↵
     2. Zhu G,
     3. Lynn GM,
     4. Jacobson O,
     5. Chen K,
     6. Liu Y,
     7. Zhang H, et al.

     Albumin/vaccine nanocomplexes that assemble in vivo for combination cancer immunotherapy. Nat Commun. 2017; 8: 1954.

     OpenUrl
114. 114.↵
     2. Paolillo G,
     3. Astarita T.

     Perspective camera model with refraction correction for optical velocimetry measurements in complex geometries. IEEE Trans Pattern Anal Mach Intell. 2020.
115. 115.↵
     2. Murthy N,
     3. Robichaud JR,
     4. Tirrell DA,
     5. Stayton PS,
     6. Hoffman AS.

     The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release. 1999; 61: 137–43.

     OpenUrlCrossRefPubMedWeb of Science
116. 116.↵
     2. Kompella UB,
     3. Amrite AC,
     4. Pacha Ravi R,
     5. Durazo SA.

     Nanomedicines for back of the eye drug delivery, gene delivery, and imaging. Prog Retin Eye Res. 2013; 36: 172–98.

     OpenUrlCrossRefPubMed
117. 117.
     2. Kuai R,
     3. Ochyl LJ,
     4. Bahjat KS,
     5. Schwendeman A,
     6. Moon JJ.

     Designer vaccine nanodiscs for personalized cancer immunotherapy. Nat Mater. 2017; 16: 489–96.

     OpenUrlPubMed
118. 118.↵
     2. Shah NJ,
     3. Najibi AJ,
     4. Shih TY,
     5. Mao AS,
     6. Sharda A,
     7. Scadden DT, et al.

     A biomaterial-based vaccine eliciting durable tumour-specific responses against acute myeloid leukaemia. Nat Biomed Eng. 2020; 4: 40–51.

     OpenUrl
119. 119.↵
     2. Min Y,
     3. Roche KC,
     4. Tian S,
     5. Eblan MJ,
     6. McKinnon KP,
     7. Caster JM, et al.

     Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat Nanotechnol. 2017; 12: 877–82.

     OpenUrl
120. 120.↵
     2. Lu Y,
     3. Lin J,
     4. Wang L,
     5. Zhang L,
     6. Cai C.

     Self-assembly of copolymer micelles: higher-level assembly for constructing hierarchical structure. Chem Rev. 2020; 120: 4111–40.

     OpenUrl
121. 121.↵
     2. Mei L,
     3. Rao J,
     4. Liu Y,
     5. Li M,
     6. Zhang Z,
     7. He Q.

     Effective treatment of the primary tumor and lymph node metastasis by polymeric micelles with variable particle sizes. J Control Release. 2018; 292: 67–77.

     OpenUrl
122. 122.↵
     2. Sapra R,
     3. Verma RP,
     4. Maurya GP,
     5. Dhawan S,
     6. Babu J,
     7. Haridas V.

     Designer peptide and protein dendrimers: a cross-sectional analysis. Chem Rev. 2019; 119: 11391–441.

     OpenUrl
123. 123.↵
     2. Mignani S,
     3. Rodrigues J,
     4. Tomas H,
     5. Zablocka M,
     6. Shi X,
     7. Caminade AM, et al.

     Dendrimers in combination with natural products and analogues as anti-cancer agents. Chem Soc Rev. 2018; 47: 514–32.

     OpenUrl
124. 124.↵
     2. Tian WD,
     3. Ma YQ.

     Theoretical and computational studies of dendrimers as delivery vectors. Chem Soc Rev. 2013; 42: 705–27.

     OpenUrl
125. 125.↵
     2. Caminade AM,
     3. Yan D,
     4. Smith DK.

     Dendrimers and hyperbranched polymers. Chem Soc Rev. 2015; 44: 3870–3.

     OpenUrl
126. 126.↵
     2. Xi X,
     3. Ye T,
     4. Wang S,
     5. Na X,
     6. Wang J,
     7. Qing S, et al.

     Self-healing microcapsules synergetically modulate immunization microenvironments for potent cancer vaccination. Sci Adv. 2020; 6: eaay7735.
127. 127.↵
     2. Pan C,
     3. Wu J,
     4. Qing S,
     5. Zhang X,
     6. Zhang L,
     7. Yue H, et al.

     Biosynthesis of self-assembled proteinaceous nanoparticles for vaccination. Adv Mater. 2020; 32: e2002940.
128. 128.↵
     2. Xia Y,
     3. Wu J,
     4. Wei W,
     5. Du Y,
     6. Wan T,
     7. Ma X, et al.

     Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination. Nat Mater. 2018; 17: 187–94.

     OpenUrl
129. 129.↵
     2. Dong X,
     3. Liang J,
     4. Yang A,
     5. Qian Z,
     6. Kong D,
     7. Lv F.

     Fluorescence imaging guided CpG nanoparticles-loaded IR820-hydrogel for synergistic photothermal immunotherapy. Biomaterials. 2019; 209: 111–25.

     OpenUrl
130. 130.↵
     2. Li S,
     3. Bennett ZT,
     4. Sumer BD,
     5. Gao J.

     Nano-immune-engineering approaches to advance cancer immunotherapy: lessons from ultra-pH-sensitive nanoparticles. Acc Chem Res. 2020; 53: 2546–57.

     OpenUrl
131. 131.↵
     2. Yi X,
     3. Xu M,
     4. Zhou H,
     5. Xiong S,
     6. Qian R,
     7. Chai Z, et al.

     Ultrasmall hyperbranched semiconducting polymer nanoparticles with different radioisotopes labeling for cancer theranostics. ACS Nano. 2018; 12: 9142–51.

     OpenUrl
132. 132.↵
     2. Xu J,
     3. Lv J,
     4. Zhuang Q,
     5. Yang Z,
     6. Cao Z,
     7. Xu L, et al.

     A general strategy towards personalized nanovaccines based on fluoropolymers for post-surgical cancer immunotherapy. Nat Nanotechnol. 2020; 15: 1043–52.

     OpenUrl
133. 133.↵
     2. Lu X,
     3. Miao L,
     4. Gao W,
     5. Chen Z,
     6. McHugh KJ,
     7. Sun Y, et al.

     Engineered PLGA microparticles for long-term, pulsatile release of STING agonist for cancer immunotherapy. Sci Transl Med. 2020; 12: eaaz6606.
134. 134.↵
     2. Conniot J,
     3. Scomparin A,
     4. Peres C,
     5. Yeini E,
     6. Pozzi S,
     7. Matos AI, et al.

     Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat Nanotechnol. 2019; 14: 891–901.

     OpenUrl
135. 135.↵
     2. Wang C,
     3. Sun W,
     4. Ye Y,
     5. Bomba HN,
     6. Gu Z.

     Bioengineering of artificial antigen presenting cells and lymphoid organs. Theranostics. 2017; 7: 3504–16.

     OpenUrl
136. 136.↵
     2. Mohammadpour R,
     3. Dobrovolskaia MA,
     4. Cheney DL,
     5. Greish KF,
     6. Ghandehari H.

     Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv Drug Deliv Rev. 2019; 144: 112–32.

     OpenUrl
137. 137.↵
     2. Luther DC,
     3. Huang R,
     4. Jeon T,
     5. Zhang X,
     6. Lee YW,
     7. Nagaraj H, et al.

     Delivery of drugs, proteins, and nucleic acids using inorganic nanoparticles. Adv Drug Deliv Rev. 2020; 156: 188–213.

     OpenUrl
138. 138.↵
     2. Croissant JG,
     3. Butler KS,
     4. Zink JI,
     5. Brinker CJ.

     Synthetic amorphous silica nanoparticles: toxicity, biomedical and environmental implications. Nat Rev Mater. 2020; 5: 886–909.

     OpenUrl
139. 139.↵
     2. Li AW,
     3. Sobral MC,
     4. Badrinath S,
     5. Choi Y,
     6. Graveline A,
     7. Stafford AG, et al.

     A facile approach to enhance antigen response for personalized cancer vaccination. Nat Mater. 2018; 17: 528–34.

     OpenUrl
140. 140.↵
     2. Wang X,
     3. Li X,
     4. Ito A,
     5. Yoshiyuki K,
     6. Sogo Y,
     7. Watanabe Y, et al.

     Hollow structure improved anti-cancer immunity of mesoporous silica nanospheres in vivo. Small. 2016; 12: 3510–5.

     OpenUrl
141. 141.↵
     2. Liu Q,
     3. Zhou Y,
     4. Li M,
     5. Zhao L,
     6. Ren J,
     7. Li D, et al.

     Polyethylenimine hybrid thin-shell hollow mesoporous silica nanoparticles as vaccine self-adjuvants for cancer immunotherapy. ACS Appl Mater Interfaces. 2019; 11: 47798–809.

     OpenUrl
142. 142.↵
     2. Yang Y,
     3. Lu Y,
     4. Abbaraju PL,
     5. Zhang J,
     6. Zhang M,
     7. Xiang G, et al.

     Multi-shelled dendritic mesoporous organosilica hollow spheres: roles of composition and architecture in cancer immunotherapy. Angew Chem Int Ed Engl. 2017; 56: 8446–50.

     OpenUrl
143. 143.↵
     2. Vallet-Regi M,
     3. Colilla M,
     4. Izquierdo-Barba I,
     5. Manzano M.

     Mesoporous silica nanoparticles for drug delivery: current insights. Molecules. 2017; 23: 47.

     OpenUrl
144. 144.↵
     2. Yang Y,
     3. Tang J,
     4. Song H,
     5. Yang Y,
     6. Gu Z,
     7. Fu J, et al.

     Dendritic mesoporous silica nanoparticle adjuvants modified with binuclear aluminum complex: coordination chemistry dictates adjuvanticity. Angew Chem Int Ed Engl. 2020; 59: 19610–7.

     OpenUrl
145. 145.↵
     2. Li X,
     3. Wang X,
     4. Ito A,
     5. Tsuji NM.

     A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. Nat Commun. 2020; 11: 3858.

     OpenUrl
146. 146.↵
     2. Ding B,
     3. Shao S,
     4. Yu C,
     5. Teng B,
     6. Wang M,
     7. Cheng Z, et al.

     Large-pore mesoporous-silica-coated upconversion nanoparticles as multifunctional immunoadjuvants with ultrahigh photosensitizer and antigen loading efficiency for improved cancer photodynamic immunotherapy. Adv Mater. 2018; 30: e1802479.
147. 147.↵
     2. Nguyen TL,
     3. Choi Y,
     4. Kim J.

     Mesoporous silica as a versatile platform for cancer immunotherapy. Adv Mater. 2019; 31: e1803953.
148. 148.↵
     2. Nguyen TL,
     3. Cha BG,
     4. Choi Y,
     5. Im J,
     6. Kim J.

     Injectable dual-scale mesoporous silica cancer vaccine enabling efficient delivery of antigen/adjuvant-loaded nanoparticles to dendritic cells recruited in local macroporous scaffold. Biomaterials. 2020; 239: 119859.
149. 149.↵
     2. Hess KL,
     3. Medintz IL,
     4. Jewell CM.

     Designing inorganic nanomaterials for vaccines and immunotherapies. Nano Today. 2019; 27: 73–98.

     OpenUrl
150. 150.↵
     2. Arun Kumar S,
     3. Good J,
     4. Hendrix D,
     5. Yoo E,
     6. Kim D,
     7. Deo KA, et al.

     Nanoengineered light-activatable polybubbles for on-demand therapeutic delivery. Adv Funct Mater. 2020; 30: 2003579.
151. 151.↵
     2. Zhu M,
     3. Du L,
     4. Zhao R,
     5. Wang HY,
     6. Zhao Y,
     7. Nie G, et al.

     Cell-penetrating nanoparticles activate the inflammasome to enhance antibody production by targeting microtubule-associated protein 1-light chain 3 for degradation. ACS Nano. 2020; 14: 3703–17.

     OpenUrl
152. 152.↵
     2. Zhou Q,
     3. Zhang Y,
     4. Du J,
     5. Li Y,
     6. Zhou Y,
     7. Fu Q, et al.

     Different-sized gold nanoparticle activator/antigen increases dendritic cells accumulation in liver-draining lymph nodes and CD8+ T cell responses. ACS Nano. 2016; 10: 2678–92.

     OpenUrlCrossRef
153. 153.↵
     2. Wang Y,
     3. Quinsaat JEQ,
     4. Ono T,
     5. Maeki M,
     6. Tokeshi M,
     7. Isono T, et al.

     Enhanced dispersion stability of gold nanoparticles by the physisorption of cyclic poly(ethylene glycol). Nat Commun. 2020; 11: 6089.

     OpenUrl
154. 154.↵
     2. Mao W,
     3. Lee S,
     4. Shin J,
     5. Yoo H.

     Surface-initiated atom transfer polymerized anionic corona on gold nanoparticles for anti-cancer therapy. Pharmaceutics. 2020; 12: 261.

     OpenUrl
155. 155.↵
     2. Goddard ZR,
     3. Marin MJ,
     4. Russell DA,
     5. Searcey M.

     Active targeting of gold nanoparticles as cancer therapeutics. Chem Soc Rev. 2020; 49: 8774–89.

     OpenUrl
156. 156.↵
     2. Kobayashi T.

     Cancer hyperthermia using magnetic nanoparticles. Biotechnol J. 2011; 6: 1342–7.

     OpenUrlCrossRefPubMedWeb of Science
157. 157.↵
     2. Rivera Gil P,
     3. Hühn D,
     4. del Mercato LL,
     5. Sasse D,
     6. Parak WJ.

     Nanopharmacy: inorganic nanoscale devices as vectors and active compounds. Pharmacol Res. 2010; 62: 115–25.

     OpenUrlCrossRefPubMed
158. 158.↵
     2. Grippin AJ,
     3. Wummer B,
     4. Wildes T,
     5. Dyson K,
     6. Trivedi V,
     7. Yang C, et al.

     Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano. 2019; 13: 13884–98.

     OpenUrl
159. 159.↵
     2. Guo Y,
     3. Ran Y,
     4. Wang Z,
     5. Cheng J,
     6. Cao Y,
     7. Yang C, et al.

     Magnetic-responsive and targeted cancer nanotheranostics by PA/MR bimodal imaging-guided photothermally triggered immunotherapy. Biomaterials. 2019; 219: 119370.
160. 160.↵
     2. Traini G,
     3. Ruiz-de-Angulo A,
     4. Blanco-Canosa JB,
     5. Zamacola Bascaran K,
     6. Molinaro A,
     7. Silipo A, et al.

     Cancer immunotherapy of TLR4 agonist-antigen constructs enhanced with pathogen-mimicking magnetite nanoparticles and checkpoint blockade of PD-L1. Small. 2019; 15: e1803993.
161. 161.↵
     2. Kroll AV,
     3. Jiang Y,
     4. Zhou J,
     5. Holay M,
     6. Fang RH,
     7. Zhang L.

     Biomimetic nanoparticle vaccines for cancer therapy. Adv Biosyst. 2019; 3: e1800219.
162. 162.↵
     2. Yoo JW,
     3. Irvine DJ,
     4. Discher DE,
     5. Mitragotri S.

     Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat Rev Drug Discov. 2011; 10: 521–35.

     OpenUrlCrossRefPubMed
163. 163.↵
     2. Luo GF,
     3. Chen WH,
     4. Zeng X,
     5. Zhang XZ.

     Cell primitive-based biomimetic functional materials for enhanced cancer therapy. Chem Soc Rev. 2021; 50: 945–85.

     OpenUrl
164. 164.↵
     2. Li M,
     3. Zhou H,
     4. Jiang W,
     5. Yang C,
     6. Miao H,
     7. Wang Y.

     Nanovaccines integrating endogenous antigens and pathogenic adjuvants elicit potent antitumor immunity. Nano Today. 2020; 35: 101007.
165. 165.↵
     2. Schwechheimer C,
     3. Kuehn MJ.

     Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat Rev Microbiol. 2015; 13: 605–19.

     OpenUrlCrossRefPubMed
166. 166.↵
     2. Ngandeu Neubi GM,
     3. Opoku-Damoah Y,
     4. Gu X,
     5. Han Y,
     6. Zhou J,
     7. Ding Y.

     Bio-inspired drug delivery systems: an emerging platform for targeted cancer therapy. Biomater Sci. 2018; 6: 958–73.

     OpenUrl
167. 167.↵
     2. Kudela P,
     3. Koller VJ,
     4. Lubitz W.

     Bacterial ghosts (BGs) – advanced antigen and drug delivery system. Vaccine. 2010; 28: 5760–7.

     OpenUrlCrossRefPubMedWeb of Science
168. 168.↵
     2. Gerritzen MJH,
     3. Martens DE,
     4. Wijffels RH,
     5. van der Pol L,
     6. Stork M.

     Bioengineering bacterial outer membrane vesicles as vaccine platform. Biotechnol Adv. 2017; 35: 565–74.

     OpenUrlCrossRef
169. 169.↵
     2. Qing S,
     3. Lyu C,
     4. Zhu L,
     5. Pan C,
     6. Wang S,
     7. Li F, et al.

     Biomineralized bacterial outer membrane vesicles potentiate safe and efficient tumor microenvironment reprogramming for anticancer therapy. Adv Mater. 2020; 32: e2002085.
170. 170.↵
     2. Holay M,
     3. Guo Z,
     4. Pihl J,
     5. Heo J,
     6. Park JH,
     7. Fang RH, et al.

     Bacteria-inspired nanomedicine. ACS Applied Bio Materials. 2020.
171. 171.↵
     2. Angsantikul P,
     3. Thamphiwatana S,
     4. Gao W,
     5. Zhang L.

     Cell membrane-coated nanoparticles as an emerging antibacterial vaccine platform. Vaccines. 2015; 3: 814–28.

     OpenUrl
172. 172.↵
     2. Parodi A,
     3. Molinaro R,
     4. Sushnitha M,
     5. Evangelopoulos M,
     6. Martinez JO,
     7. Arrighetti N, et al.

     Bio-inspired engineering of cell- and virus-like nanoparticles for drug delivery. Biomaterials. 2017; 147: 155–68.

     OpenUrl
173. 173.↵
     2. Zhou J,
     3. Kroll AV,
     4. Holay M,
     5. Fang RH,
     6. Zhang L.

     Biomimetic nanotechnology toward personalized vaccines. Adv Mater. 2020; 32: e1901255.
174. 174.↵
     2. Ukidve A,
     3. Zhao Z,
     4. Fehnel A,
     5. Krishnan V,
     6. Pan DC,
     7. Gao Y, et al.

     Erythrocyte-driven immunization via biomimicry of their natural antigen-presenting function. Proc Natl Acad Sci U S A. 2020; 117: 17727–36.

     OpenUrlAbstract/FREE Full Text
175. 175.↵
     2. Liu Y,
     3. Luo JS,
     4. Chen XJ,
     5. Liu W,
     6. Chen TK.

     Cell membrane coating technology: a promising strategy for biomedical applications. Nanomicro Lett. 2019; 11: 100.

     OpenUrl
176. 176.↵
     2. Hu QY,
     3. Bomba HN,
     4. Gu Z.

     Engineering platelet-mimicking drug delivery vehicles. Front Chem Sci Eng. 2017; 11: 624–32.

     OpenUrl
177. 177.↵
     2. Cheng S,
     3. Xu C,
     4. Jin Y,
     5. Li Y,
     6. Zhong C,
     7. Ma J, et al.

     Artificial mini dendritic cells boost T cell-based immunotherapy for ovarian cancer. Adv Sci (Weinh). 2020; 7: 1903301.
178. 178.↵
     2. Zhang Z,
     3. Li D,
     4. Li X,
     5. Guo Z,
     6. Liu Y,
     7. Ma X, et al.

     PEI-modified macrophage cell membrane-coated PLGA nanoparticles encapsulating Dendrobium polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses. Int J Biol Macromol. 2020; 165: 239–48.

     OpenUrl
179. 179.↵
     2. Wang L,
     3. Pegram MD,
     4. Wu JC.

     Induced pluripotent stem cells as a novel cancer vaccine. Expert Opin Biol Ther. 2019; 19: 1191–7.

     OpenUrl
180. 180.↵
     2. Zhang M,
     3. Zang X,
     4. Wang M,
     5. Li Z,
     6. Qiao M,
     7. Hu H, et al.

     Exosome-based nanocarriers as bio-inspired and versatile vehicles for drug delivery: recent advances and challenges. J Mater Chem B. 2019; 7: 2421–33.

     OpenUrl
181. 181.↵
     2. Fang RH,
     3. Jiang Y,
     4. Fang JC,
     5. Zhang L.

     Cell membrane-derived nanomaterials for biomedical applications. Biomaterials. 2017; 128: 69–83.

     OpenUrl
182. 182.↵
     2. Harris JC,
     3. Scully MA,
     4. Day ES.

     Cancer cell membrane-coated nanoparticles for cancer management. Cancers. 2019; 11: 1836.

     OpenUrl
183. 183.↵
     2. Huh YM,
     3. Lee ES,
     4. Lee JH,
     5. Jun Yw,
     6. Kim PH,
     7. Yun CO, et al.

     Hybrid nanoparticles for magnetic resonance imaging of target-specific viral gene delivery. Adv Mater. 2007; 19: 3109–12.

     OpenUrl
184. 184.↵
     2. Roldao A,
     3. Mellado MC,
     4. Castilho LR,
     5. Carrondo MJ,
     6. Alves PM.

     Virus-like particles in vaccine development. Expert Rev Vaccines. 2010; 9: 1149–76.

     OpenUrlCrossRefPubMedWeb of Science
185. 185.↵
     2. Ong HK,
     3. Tan WS,
     4. Ho KL.

     Virus like particles as a platform for cancer vaccine development. PeerJ. 2017; 5: e4053.
186. 186.↵
     2. Hodgson CP,
     3. Solaiman F.

     Virosomes: cationic liposomes enhance retroviral transduction. Nat Biotechnol. 1996; 14: 339–42.

     OpenUrlCrossRefPubMed
187. 187.↵
     2. Gargett T,
     3. Grubor-Bauk B,
     4. Miller D,
     5. Garrod T,
     6. Yu S,
     7. Wesselingh S, et al.

     Increase in DNA vaccine efficacy by virosome delivery and co-expression of a cytolytic protein. Clin Transl Immunology. 2014; 3: e18.
188. 188.↵
     2. Mitchell MJ,
     3. Billingsley MM,
     4. Haley RM,
     5. Wechsler ME,
     6. Peppas NA,
     7. Langer R.

     Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021; 20: 101–24.

     OpenUrlCrossRef